ArticleBJUI compass2026
The use of biparametric magnetic resonance imaging in active surveillance of prostate cancer.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to evaluate the performance of biparametric magnetic resonance imaging (bpMRI) compared to multiparametric MRI (mpMRI) for active surveillance (AS) in prostate cancer (PCa), focusing on lesion detection, PI-RADS classification changes and grade reclassification (GR) rates. Methods: We retrospectively reviewed our institutional AS database for men who underwent mpMRI followed by bpMRI. Lesion counts and PI-RADS classification were compared. Second, a subgroup of men who underwent mpMRI, biopsy, bpMRI and then repeat biopsy ('bpMRI biopsy group') was matched to a control group who underwent mpMRI, biopsy, another mpMRI and then repeat biopsy ('mpMRI biopsy group') based on age, PSA density, year of diagnosis and number of positive cores. GR rates at systematic and targeted biopsy of all PI-RADS 3-5 lesions were compared, as were PI-RADS changes. Results: A total of 129 men with a median of 29 months between mpMRI and bpMRI were included. mpMRI identified 77 PI-RADS 3-5 lesions versus 114 on subsequent bpMRI (0.60 vs. 0.88 lesions/patient, Conclusions: bpMRI appears safe to incorporate into AS over the short term, as it was noninferior to mpMRI with similar GR rates and lesion stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.